Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression

Journal of the National Cancer Institute

Volumn 91, Issue 6, 1999, Pages 512-523

  Mukherjee, Purna ^a   Sotnikov, Alexander V ^a   Mangian, Heather J ^b   Zhou, Jin Rong ^e   Visek, Willard J ^b   Clinton, Steven K ^c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; SOMATOMEDIN C; VASCULOTROPIN RECEPTOR;

ANDROGEN BLOOD LEVEL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALORIC INTAKE; CARBOHYDRATE INTAKE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT INTAKE; GENE EXPRESSION; HYPOTHESIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SCID MOUSE; TUMOR GROWTH; TUMOR MODEL;

EID: 0033577233     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.6.512     Document Type: Article

References (65)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997;47:68]. CA Cancer J Clin 1997;47:5-27.
2. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
3. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968;40:43-68.
4. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:557-63.
5. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, el al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652-61.
6. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732-40.
7. Fund WC. Food, nutrition and the prevention of cancer: a global perspective. Washington (DC): American Institute for Cancer Research; 1997
8. Clinton SK, Giovannucci E. Diet, nutrition, and prostate cancer. Ann Rev Nutr 1998;18:413-40.
9. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563-76.
10. Talamini R, La Vecchia C, Decarli A, Negri E, Franceschi S. Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer 1986;53:817-21.
11. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984;120:244-50.
12. Thompson TC, Southgate J, Kitchner G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56: 917-30.
13. Andersson SO, Wolk A, Bergstrom R, Giovannucci E, Lindgren C, Baron J, et al. Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 1996;68:716-22.
14. Severson RK, Grove JS, Nomura AM, Stemmermann GN. Body mass and prostatic cancer: a prospective study. BMJ 1988;297:713-5.
15. Andersson SO, Baron J, Wolk A, Lindgren C, Bergstron R, Adami HO. Early life risk factors for prostate cancer: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1995;4:187-92.
16. Rosenbaum M, Leibel RL, Hirsch J. Obesity [published erratum appears in N Engl J Med 1998;338:555]. N Engl J Med 1997;337:396-407.
17. Rao GN, Haseman JK, Grumbein S, Crawford DD, Eustis SL. Growth, body weight, survival, and tumor trends in F344/N rats during an eleven-year period. Toxicol Pathol 1990;18:61-70.
18. Smolev JK, Heston WD, Scott WW, Coffey DS. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep 1977;61:273-87.
19. Isaacs JT, Coffey DS. Animal models for the study of prostatic cancer. Cancer Detect Prev 1979;2:587-99.
20. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41: 5070-5.
21. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostate carcinoma. Cancer Res 1983;43: 1809-18.
22. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
23. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-53.
24. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2: 689-92.
25. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
26. Cohen P, Peehl CM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
27. Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes with an increase in IGF binding protein 3. Cancer Res 1998;58:215-8.
28. Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992;92: 141-9.
29. Ferrara N, Davissmyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997;18:4-25.
30. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997;386:403-7.
31. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
32. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A 1995;92:768-72.
33. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507-11.
34. American Institute of Nutrition. Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1977;107:1340-8.
35. American Institute of Nutrition. Second report of the Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1980;110:1726.
36. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;19:493-501.
37. Steel RG, Torrie JH. Principles and procedures of statistics: a biometrical approach. New York (NY): McGraw-Hill; 1980.
38. Scheffe H. A method for judging all contrasts in the analysis of variance. Biometrika 1953;40:87-104.
39. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329-33.
40. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-6.
41. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-8.
42. McCay CM, Maynard LA, Sperling G, Barnes LL. Retarded growth, life span, ultimate body size and age changes in the albino rat after feeding diets restricted in calories. J Nutr 1939;18:1-13.
43. Tannenbaum A. The dependence of tumor formation on the composition of the calorie-restricted diet as well as on the degree of restriction. Cancer Res 1945;5:616-25.
44. Weindruch R, Walford R. The retardation of aging and disease by dietary restriction. Springfield (IL): Charles C. Thomas Publ.; 1988.
45. Clinton SK, Palmer SS, Spriggs CE, Visek WJ. The growth of Dunning transplantable prostate adenocarcinomas in rats fed diets with various fat contents. J Nutr 1988;118:908-14.
46. Rose DP, Cohen LA. Effects of dietary menhaden oil and retinyl acetate on the growth of DU 145 human prostatic adenocarcinoma cells transplanted into athymic nude mice. Carcinogenesis 1988;9:603-5.
47. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991;18:243-54.
48. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995;87:1456-62.
49. Birt DF, Pinch HJ, Barnett T, Phan A, Dimitroff K. Inhibition of skin tumor promotion by restriction of fat and carbohydrate calories in SENCAR mice. Cancer Res 1993;53:27-31.
50. Lavik PS, Baumann CA. Further studies on the tumor promoting action of fat. Cancer Res 1943;3:749-56.
51. Kritchevsky D, Weber MM, Klurfeld DM. Dietary fat versus caloric content in initiation and promotion of 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats. Cancer Res 1984;44: 3174-7.
52. Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW. Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res 1989;49:4130-4.
53. Klurfeld DM, Lloyd LM, Welch CB, Davis MJ, Tulp OL, Kritchevsky D. Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc Soc Exp Biol Med 1991;196:381-4.
54. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;4:437-12.
55. Lu C, Tanigawa N. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma. Cancer Res 1997;57: 221-4.
56. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
57. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333: 1757-63.
58. Hursting SD, Switzer BR, French JE, Kari FW. The growth hormone: insulin-like growth factor I axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Res 1993; 53:2750-7.
59. Dunn SE, Kari FW, French J, Leininger JR, Travols G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-72.
60. Kluge A, Zimmermann R, Munkel B, Mohri M, Sack S, Schaper J, et al. Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res 1995; 29:407-15.
61. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552-62.
62. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-22.
63. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
64. Landstrom M, Damber JE, Bergh A. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res 1994;54:4281-4.
65. English HF, Kloszewski ED, Valentine EG, Santen RJ. Proliferative response of the Dunning R3327H experimental model of prostatic adenocarcinoma to conditions of androgen depletion and repletion. Cancer Res 1986;46:839-44.